TickerTalks
Browse all tickers →
TickerTalks›$AZN
AZAZN

AstraZeneca PLC

$AZN·$247B·Drug Manufacturers - General·Healthcare
$165.75-0.6%YTD-9.9%1Y-0.8%
Price updated 3m ago·X counts updated 5d ago
AZAZN
$AZNAstraZeneca PLC
$165.76-0.55%174 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $AZN on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

174X posts · last 7 days
Sep 28Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $AZN's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data7 posts analyzed · as of 2026-09-15

AstraZeneca's tozorakimab cuts COPD exacerbations in Phase III with FDA BLA accepted using a Priority Review Voucher, and Dellphi-305 Imfinzi + Imdelltra tops-line positive in 1L ES-SCLC. CEO reiterates peak-sales potential above $5B supporting the $80B 2030 revenue target.

Read what X is saying about $AZN

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $AZN — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersWinding up for a moveAI verdict · as of 2026-10-02

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

AstraZeneca is near 52-week lows while tozorakimab for COPD just got FDA Priority Review — the pipeline is doing what the stock isn't.

AstraZeneca is the global biopharma — oncology (Tagrisso, Imfinzi, Enhertu), respiratory (Symbicort, tozorakimab), and rare-disease via Alexion. The pipeline is firing; the stock is in a drawdown.

  • Operations are strong: Q1 revenue +12.5% YoY at a 23.5% operating margin and ROIC of 12.9% — top-line growth plus margin stability is a quality-biopharma profile that typically rerates higher.
  • The pipeline wins are specific and dated: tozorakimab Phase III cut COPD exacerbations with FDA BLA accepted using a Priority Review Voucher, and the Imfinzi + Imdelltra Dellphi-305 trial just read out positive in 1L extensive-stage small-cell lung cancer — tangible regulatory and clinical signals.
  • 52-week range position is 13% at $157.70 — this is near-capitulation for a quality global pharma, which is why management reiterating the $80B 2030 revenue target feels defensive, with the stock not giving credit yet.

Oct 30 Q3 is the gate — any continued revenue growth plus pipeline cadence updates on tozorakimab, Dellphi-305, and Enhertu extend the stock off the floor. A guide reset or a safety signal on any flagship program and the stock stays range-bound at the lows.

Agrees with X sentimentThe thread has substantive drivers — tozorakimab Phase III positive in COPD with FDA Priority Review Voucher acceptance, Dellphi-305 Imfinzi + Imdelltra positive 1L ES-SCLC, management's $80B 2030 revenue target and $5B peak-sales commentary — all specific regulatory and clinical signals.

What to watch: Oct 30 Q3 — overall revenue growth, tozorakimab regulatory progress, Dellphi-305 implications for 2027 revenue, operating-margin trajectory, and any 2030 outlook. A guide reset or safety signal is the clear invalidator.

On the calendar: 2026-10-30 — Q3 earnings

Read the AI verdict on $AZN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Large pharma/biotech with strong oncology (Tagrisso, Enhertu), cardiovascular, and respiratory drug portfolios.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $AZN.

Drug Manufacturers - General · Healthcare

No material change from last week — GLP-1 duopoly (LLY/NVO) drives premium valuations while patent-cliff management defines the rest: ABBV migraine franchise win strengthens post-Humira portfolio.

What this means for $AZN

Neutral — Large pharma/biotech with strong oncology (Tagrisso, Enhertu), cardiovascular, and respiratory drug portfolios.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+14.5%YTD
+36.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
27.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
12.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
23.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
3.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
4.7Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
22.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
79.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 27, 2026$2.63$2.50+5.2%
Q1 2026Apr 29, 2026$2.58$2.57+0.4%
Q4 2025Feb 10, 2026$2.12$2.09+1.4%
Q3 2025Nov 6, 2025$2.38$2.28+4.4%
Next earningsFri, Oct 30·consensus EPS $2.60

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$15.3B+12.5%82.5%27.8%$1.99$1.8B
Q4 FY25$15.5B+4.1%79.9%19.2%$1.51$1.4B
Q3 FY25$15.2B+12.0%81.6%23.6%$1.63$4.4B
Q2 FY25$14.5B+11.7%82.9%24.3%$1.58$1.5B

Forward consensus

5-year forecast · up to 21 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$62.9B$61.7B – $63.6B$10.26$5.64 – $11.3418
FY27$66.9B$63.9B – $68.1B$11.44$6.25 – $12.8119
FY28$71.1B$66.7B – $74.4B$12.76$9.67 – $14.0021
FY29$76.8B$72.8B – $78.7B$14.66$13.66 – $15.1210
FY30$81.7B$77.5B – $83.7B$16.42$15.30 – $16.9410

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.22%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+2.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-7.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 1.5B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.215-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyAug 8Mani SharmaSee Remarks20 sh$3KSellMay 20Mani SharmaSee Remarks11.9K sh$2.2M
+ 6 other (6 awards) in window

See when $AZN insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

No material 8-K / SC 13D / S-3 / 424B5 filings in the last 180 days.

+ 64 other (61 6-Ks · 1 11-K · 1 25-NSE · 1 13G) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Astrazeneca (AZN) Rises Higher Than Market: Key Factszacks.com·21h agoRBC keeps AstraZeneca at ‘outperform' ahead of AVANZAR lung cancer trialproactiveinvestors.com·1d agoAstrazeneca Plc $AZN Stock: B. Riley Wealth Advisors Inc. Increases Stakedefenseworld.net·2d agoAstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpointdefenseworld.net·3d agoAstraZeneca PLC (AZN) Presents at American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting Transcriptseekingalpha.com·4d ago

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$OGN$LLY$NVO$PFE$JNJ$ABBV$MRK$BMY
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport